Breaking News
Upgrade 0
💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains instead Unlock them all
Close

Bristol-Myers Squibb Company (BMY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
44.40 -0.23    -0.52%
06/09 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US1101221083 
S/N:  850501
  • Volume: 200
  • Bid/Ask: 43.81 / 44.00
  • Day's Range: 44.40 - 44.70
Bristol-Myers Squibb 44.40 -0.23 -0.52%

BMY Income Statement

 
Featured here, the Income Statement (earnings report) for Bristol-Myers Squibb Company, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
Advanced Income Statement
Period Ending: 2024
30/06
2024
31/03
2023
31/12
2023
30/09
Total Revenue 12201 11865 11477 10966
Revenue 12201 11865 11477 10966
Other Revenue, Total - - - -
Cost of Revenue, Total 2971 2910 2707 2490
Gross Profit 9230 8955 8770 8476
Total Operating Expenses 9603 9581 9525 8862
Selling/General/Admin. Expenses, Total 1921 1968 2064 1938
Research & Development 2295 2346 2476 2178
Depreciation / Amortization 12 - - -
Interest Expense (Income) - Net Operating -525 -428 -311 -280
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 2929 2785 2589 2536
Operating Income 2598 2284 1952 2104
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets 74 71 78 -
Other, Net 1238 13729 200 -33
Net Income Before Taxes 1286 -11516 1674 2137
Provision for Income Taxes -398 392 -88 203
Net Income After Taxes 1684 -11908 1762 1934
Minority Interest 54 58 55 64
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 1680 -11911 1762 1928
Total Extraordinary Items - - - -
Net Income 1680 -11911 1762 1928
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items 1680 -11911 1762 1928
Dilution Adjustment -4.07 4.47 -1.01 8.48
Diluted Net Income 1684.07 -11915.47 1763.01 1919.52
Diluted Weighted Average Shares 2029 2023 2033 2064
Diluted EPS Excluding Extraordinary Items 0.829 -5.89 0.867 0.93
DPS - Common Stock Primary Issue 0.6 0.6 0.6 0.57
Diluted Normalized EPS 0.816 0.759 0.714 0.761
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BMY Comments

Write your thoughts about Bristol-Myers Squibb Co
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email